While not yet approved for addiction treatment, GLP-1RAs hold significant potential in addressing addictions complex neurobiological underpinnings
They are generally not recommended for patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), those who are pregnant or breastfeeding or planning pregnancy, patients with a known allergy to the medication, severe gastroparesis or serious digestive motility disorders, active pancreatitis or significant pancreatitis history, serious gallbladder disease, certain kidney conditions, or active eating disorder concerns
CAUTION: Please consult your physician before use if you are pregnant or nursing, under the age of 18, or are undergoing treatment for a medical condition
Ipamorelin's mechanisms suggest that it may not increase hunger compared to other similar peptides
J.Muoz-LobatoF.Parrado-FernndezC.et al